Tyler Risom
Genentech · 72 works · 3,339 citations · h-index 20
Top works
- Whole-cell segmentation of tissue images with human-level performance using large-scale data annotation and deep learning
- Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models
- MIBI-TOF: A multiplexed imaging platform relates cellular phenotypes and tissue structure
- Transition to invasive breast cancer is associated with progressive changes in the structure and composition of tumor stroma
- Evolutionary Conservation of MicroRNA Regulatory Circuits: An Examination of MicroRNA Gene Complexity and Conserved MicroRNA-Target Interactions through Metazoan Phylogeny
- MicroRNAs in mammalian development
- Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer
- MITI minimum information guidelines for highly multiplexed tissue images
- Pyrazolopyridine Inhibitors of B-RafV600E. Part 1: The Development of Selective, Orally Bioavailable, and Efficacious Inhibitors
- Discovery of pyrrolopyrimidine inhibitors of Akt
- Pyrazolopyridine inhibitors of B-RafV600E. Part 2: Structure–activity relationships
- Discovery of dihydrothieno- and dihydrofuropyrimidines as potent pan Akt inhibitors
- Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal Adenocarcinoma
- Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts
- Discovery and SAR of spirochromane Akt inhibitors
- Modeling differentiation-state transitions linked to therapeutic escape in triple-negative breast cancer
- Deregulating MYC in a model of HER2+ breast cancer mimics human intertumoral heterogeneity
- Multiplexed imaging analysis of the tumor-immune microenvironment reveals predictors of outcome in triple-negative breast cancer
- Temporal and spatial composition of the tumor microenvironment predicts response to immune checkpoint inhibition
- Pyrazolopyridine inhibitors of B-RafV600E. Part 4: Rational design and kinase selectivity profile of cell potent type II inhibitors